Krystal Biotech Inc (NASDAQ:KRYS) reported upbeat earnings for the first quarter on Monday.



The company posted quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $1.39 per share. The company reported quarterly sales of $116.357 million which beat the analyst consensus estimate of $112.132 million.



“Following a successful 2025, we are entering 2026 with strong momentum, including two potential registrational study readouts and continued global expansion for VYJUVEK,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech. “With three pipeline products receiving platform designation, each development milestone strengthens the regulatory dataset, which could accelerate future programs and potentially reduce development risk. This compounding advantage underscores the value of the platform model we have been building since day one.”



Krystal Biotech shares fell 1% to trade at $284.01 on Tuesday.



These analysts made changes to their price targets on Krystal Biotech following earnings announcement.



<ul>
<li>Evercore ISI Group analyst Gavin Clark-Gartner maintained Krystal Biotech with an Outperform rating and raised the price target from $295 to $300.</li>



<li>Citigroup analyst Yigal Nochomovitz maintained the stock with a Buy and raised the price target from $371 to $378.</li>
</ul>



Considering buying KRYS stock? Here’s what analysts think: 



<figure class="wp-block-image size-large is-resized"></figure>



Photo via Shutterstock

KRYS

Krystal Biotech (KRYS) reported strong Q1 earnings, with earnings of $1.83 per share and sales of $116.357 million, both exceeding analyst estimates. Despite a 1% drop in shares to $284.01, analysts have raised their price targets, with Evercore ISI maintaining an Outperform rating and increasing the target from $295 to $300, while Citigroup raised its Buy target from $371 to $378. CEO Krish S. Krishnan highlighted the company's momentum and potential for future growth with ongoing global expansion and pipeline developments.

benzinga_article

Krystal Biotech

VanEck Biotech ETF

iShares Global Healthcare

iShares US Pharma

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

VG Health

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Ark Genomic Revolution ETF

Evercore

Citigroup

NASDAQ Composite Index

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results